Fig. 2.

Relationship between MO/DC function and encapsulated doxorubicin CL in patients presented in a linear regression model. Measuring phagocytosis and production of ROS of MO/DC from patient blood samples at baseline (prior to the start of chemotherapy) was used as a phenotypic probe of MPS function and encapsulated doxorubicin CL. Each open circle represents an individual patient, and the solid line is the regression line. (A) Phagocytic activity (MFI) is significantly correlated with CL of encapsulated doxorubicin in 10 patients (R² = 0.43, P = 0.04). (B) Production of reactive oxygen species: MFI is significantly correlated with CL of encapsulated doxorubicin in 10 patients (R² = 0.61, P = 0.008). (C) Phagocytic activity: MFI is significantly correlated with CL of encapsulated doxorubicin in six patients receiving PLD alone (R² = 0.57, P = 0.03). (D) Production of reactive oxygen species: MFI is significantly correlated with CL of encapsulated doxorubicin in six patients receiving PLD alone (R² = 0.61, P = 0.001).